Personalized mRNA and neoantigen vaccines in oncology

mRNA technology has experienced its global breakthrough as a result of the COVID-19 pandemic and has long been clinically established. In oncology, however, the actual translation is only now beginning. Opportunities and risks are closely linked – from precise immune activation to the challenge of tumor heterogeneity. Preclinical models demonstrate the potential of mRNA and neoantigen vaccines; clinical studies and congress reports show promising results in melanoma, pancreatic carcinoma, endometrial carcinoma and other tumor entities.